Metallo-β-lactamase (MBL)-producing Enterobacteriaceae , particularly those that coharbor serine β-lactamases, are a serious emerging public health threat given their rapid dissemination and the limited number of treatment options. Preclinical and anecdotal clinical data support the use of aztreonam in combination with ceftazidime-avibactam against these pathogens, but other aztreonam-based combinations have not been explored.
16 November 2019 in Current Infectious Disease Reports
Treatment of patients with serious infections due to resistant Gram-negative bacteria remains highly problematic and has prompted clinicians to use existing antimicrobial agents in innovative ways. One approach gaining increased therapeutic use is combination therapy with IV fosfomycin. This article reviews the preclinical pharmacokinetic/pharmacodynamic (PK/PD) infection model and clinical data surrounding the use of combination therapy with IV fosfomycin for the treatment of serious infections caused by resistant Gram-negative bacteria. Data from dynamic in vitro and animal infection model studies of highly resistant Enterobacterales and non–lactose fermenters are positive and suggest IV fosfomycin in combination with a β-lactam, polymyxin or aminoglycoside produces a synergistic effect that rivals or surpasses that of other aminoglycoside- or polymyxin-containing regimens. Clinical studies performed to date primarily have involved patients with pneumonia and/or bacteraemia due to Klebsiella pneumoniae, Pseudomonas aeruginosa or Acinetobacter baumannii. Overall, the observed success rates with fosfomycin combination regimens were consistent with those reported for other combination regimens commonly used to treat these patients. In studies in which direct treatment comparisons can be derived, the results suggest that patients who received fosfomycin combination therapy had similar or improved outcomes compared with other therapies and combinations, especially when it was used in combination with a β-lactam that (1) targets PBP-3 and (2) has exceptional stability in the presence of β-lactamases. Collectively, the data indicate that combination therapy with IV fosfomycin should be considered as a potential alternative to aminoglycoside or polymyxin combinations for patients with antibiotic-resistant Gram-negative infections when benefits outweigh risks.
Despite advancements in therapy, pneumonia remains the leading cause of death due to infectious diseases. Novel treatment strategies are desperately needed to optimize the antimicrobial therapy of patients suffering from this disease. One such strategy that has recently garnered significant attention is the use of inhaled antibiotics to rapidly achieve therapeutic concentrations directly at the site of infection. In particular, there is significant interest in the role of inhaled polymyxins for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, due to their retained activity against multi-drug resistant Gram-negative pathogens, including Acinetobacter baumannii and Pseudomonas aeruginosa. This review will provide a comprehensive overview of the pharmacokinetic/pharmacodynamic profile, clinical outcomes, safety, and potential role of inhaled polymyxins in clinical practice.
1 December 2019 in Antimicrobial Agents and Chemotherapy
The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid-organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated.
1 January 2019 in The Journal of Applied Laboratory Medicine
Therapeutic drug monitoring for vancomycin is in the midst of a paradigm shift from targeting trough concentrations to area under the concentration–time curve (AUC)2. The 2009 consensus review of vancomycin therapeutic drug monitoring recommended targeting trough concentrations of 15–20 mg/L to “improve tissue penetration, increase probability of obtaining optimal target serum concentrations, and improve clinical outcomes” (1). This was a level IIIB recommendation based almost entirely on expert opinion, as previous studies had demonstrated that troughs were not associated with efficacy (2). However, studies had demonstrated that trough concentrations, especially those ≥15 mg/L, were a reliable marker of increased risk of vancomycin-associated nephrotoxicity (2, 3). Conversely, AUC values and AUC/minimum inhibitory concentration (MIC) ratios had been associated with clinical efficacy (4), but no definitive upper threshold for nephrotoxicity had been established. This discordance between guideline recommendations and current literature caused a clinical dilemma, as it was known that trough concentrations have …